By Faith Ashmore, Benzinga
BioSig Technologies, Inc. (NASDAQ: BSGM) is a groundbreaking medical technology company that specializes in providing precision and accuracy in visualizing intracardiac signals. Recently, their subsidiary, BioSig AI Sciences, Inc. (BAIS), was chosen to join NVIDIA Inception. This prestigious program is designed to partner with companies that are revolutionizing industries through advancements in AI and data sciences.
By being a part of NVIDIA Inception, BioSig AI Sciences gains access to valuable resources during critical stages of product development, prototyping and deployment. This includes engineering guidance, technical training, hardware and software support, co-marketing opportunities and exposure to the NVIDIA investment community. Leveraging NVIDIA's (NASDAQ: NVDA) vast array of tools and frameworks, BioSig AI Sciences aims to advance the research and development of its AI medical device platform for the healthcare industry.
Ken Londoner, Chairman, CEO and Founder of BioSig, expressed excitement in joining this exclusive group of AI-centric technology companies, sharing “We are thrilled to join an elite group of AI-centric technology companies leading the evolution of machine learning and artificial intelligence across industries. NVIDIA Inception will help advance BioSig’s role in identifying transformational applications of artificial intelligence opportunities in healthcare.”
BioSig AI Sciences is currently training its AI platform using electrocardiogram (ECG) and intracardiac electrogram (IECG) data from BioSig's patented PURE EP™ Platform. BioSig reports that this platform has been utilized in over 3,500 procedures and has been featured in peer-reviewed clinical research. By incorporating various data modalities including time series, text, image, video, and other clinically relevant signals, BioSig AI Sciences aims to assist healthcare systems in developing and deploying a comprehensive AI model that can understand structured, semi-structured and unstructured medical data.
BioSig’s platform is aligned with the growth of artificial intelligence in the healthcare industry. In 2022, the market for AI in healthcare was valued at around $9.6 billion. However, experts predict that this market will experience a remarkable surge and it is projected to reach $272.9 billion by the year 2030. This growth is expected to occur at an impressive compound annual growth rate (CAGR) of 51.9% during the forecast period.
BioSig Technologies seems well-positioned to help revolutionize the treatment of cardiovascular arrhythmias. By working closely with renowned physicians, experts and healthcare leaders in the field of electrophysiology (EP), BioSig Technologies is dedicated to tackling some of the most crucial challenges in healthcare, which include saving time, reducing costs and ultimately saving lives. Its latest partnership with NVIDIA seems indicative of the company’s focus on growth.
This post contains sponsored content. This content is for informational purposes only and not intended to be investing advice.
View source version on newsdirect.com: https://newsdirect.com/news/nvidia-inception-chooses-biosig-ai-for-innovation-in-healthcare-ai-an-industry-that-is-projected-to-reach-272-9-billion-by-2030-160337047